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INTRODUCTION
Aprotinin, a non-specific serine protease inhibitor, has a
molecular weight of 6,000 dalton and is extracted from a bo-
vine lung. This drug has both anti-inflammatory and hemo-
static effects. After being introduced for the treatment of acute
pancreatitis in the 1950s, aprotinin had mostly been used for
controlling clinical conditions with whole body inflammation
such as hemorrhagic shock, multiple traumas, and acute res-
piratory distress syndrome. It was not until the early 1980s
that aprotinin became widely used in the field of cardiovas-
cular surgery as a hemostatic agent (1). Recently, there have
been several reports regarding the anti-inflammatory effect
of aprotinin, and one of the most outstanding observations
is the beneficial effect of aprotinin for the patients with a func-
tional single ventricle (2). 
Cardiopulmonary bypass (CPB) is generally believed to
cause an increase in pulmonary vascular resistance (PVR),
which is sometimes fatal after one ventricle repair. The use
of aprotinin may be helpful by attenuating post-bypass ele-
vation of PVR in this setting. Aprotinin prevents CPB-indu-
ced lung injury through several mechanisms: inhibition of
thromboxane A2 release by protecting the glycoprotein Ib
receptor in platelets (3, 4), inhibition of endothelin-1 secre-
tion from pulmonary vascular endothelium (5), and suppres-
sion of complement and neutrophil activation. Platelets are
easily activated in patients with cyanotic congenital heart
disease because the concentration of the glycoprotein Ib recep-
tor is lower than normal (6). Therefore, aprotinin can be par-
ticularly useful in cyanotic patients with a functional single
ventricle necessitating one ventricle repair. 
There are several studies pertaining to the prevention of
CPB-induced lung injury: elimination of leukocytes in bypass
circuit by anti-leukocyte agents (mustine hydrochloride) or
a leukocyte filter (7), prevention of leukocyte adhesion to pul-
monary endothelium (8), addition of oxygen free radical scav-
engers (vitamin E, coenzyme Q, vitamin C, glutathione) (9),
utilization of cyclooxygenase antagonists (indomethacin), th-
romboxane A1 synthetase antagonist (dazmegral) (10), pla-
telet activation factor inhibitors (11), and steroid administra-
tion (12, 13). Although these methods may help to protect
the pulmonary vascular bed to some extent, the clinical appli-
cation of these agents is limited due to unproven safety and
cost-effectiveness. Ultrafiltration after cardiopulmonary by-
pass, either conventional or modified, is believed to be an
effective measure to ameliorate inflammatory reactions by
eliminating inflammatory mediators (14, 15). This newly de-
veloped technique, however, focuses on the treatment, rather
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Aprotinin Attenuates the Elevation of Pulmonary Vascular Resistance
After Cardiopulmonary Bypass
Pulmonary vascular resistance (PVR) is generally believed to be elevated after car-
diopulmonary bypass (CPB) due to whole body inflammation. Aprotinin has an anti-
inflammatory action, and it was hypothesized that aprotinin would attenuate the PVR
increase induced by CPB. Ten mongrel dogs were placed under moderately hypo-
thermic CPB for 2 hr. The experimental animals were divided into a control group
(n=5, group I) and an aprotinin group (n=5, group II). In group II, aprotinin was admini-
stered during pre-bypass (50,000 KIU/kg) and post-bypass (10,000 KIU/kg) periods.
Additional aprotinin (50,000 KIU/kg) was mixed in CPB priming solution. PVRs at
pre-bypass and post-bypass 0, 1, 2, 3 hr were calculated, and lung tissue was ob-
tained after the experiment. Post-bypass PVRs were significantly higher than pre-
bypass levels in all animals (n=10, p<0.001). PVR elevation in group II was less than
in group I at 3 hr post-bypass (p=0.0047). Water content of the lung was lower in
group II (74±9.4%) compared to that of group I (83±9.5%), but the difference did
not reach significance (p=0.076). Pathological examination showed a near normal
lung structure in group II, whereas various inflammatory reactions were observed
in group I. We concluded that aprotinin may attenuate CPB-induced PVR elevation
through its anti-inflammatory effect. 
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than the prevention, of systemic inflammatory response. Apro-
tinin is safe and cost-effective because it has been widely used
as a hemostatic agent in open heart surgery, and aprotinin
use can be further extended if it proves to prevent post-bypass
lung injuries. I postulated that post-bypass elevation of PVR
can be reduced by the administration of aprotinin. Therefore,
the degree of post-bypass PVR elevation in the control group
and the aprotinin treatment group was compared using a
canine cardiopulmonary bypass model. 
MATERIALS AND METHODS
Experimental animals and CPB circuit
Ten male mongrel dogs, each weighing about 20 kg (18-
23 kg) were divided into a control group (n=5, Group I) and
an aprotinin administration group (n=5, Group II). After the
administraion of sodium thiopental (25 mg/kg) and endotra-
cheal intubation, the experimental animals were laid in supine
positions and anesthesia was maintained with enflurane, N2O
and O2. The initial ventilator setting was a tidal volume of
15 mL/kg, a frequency of 16/min and FiO2 of 0.3, and it was
modulated according to the arterial blood gas analysis to main-
tain pH, PaO2 and PaCO2 close to 7.4, 100 mmHg and 40
mmHg, respectively. Pre-bypass hematocrit ranged from 45%
to 55%, and there was no difference in the hematocrit levels
between the two groups. A femoral arterial catheter was intro-
duced to monitor arterial pressure, and a Foley catheter was
placed. Through median sternotomy, the superior vena cava
was dissected and a Swan-Ganz catheter (Edward true size
pediatric thermodilution catheter, 5F, model 132F5, Baxter,
Irvin, CA, U.S.A.) was inserted via a purse-string suture made
in the superior vena cava with 6-0 prolene. The distal end of
the catheter was positioned in the main pulmonary artery to
assess cardiac output (C.O.) and pulmonary artery pressure
(PAP). For the calculation of cardiac output, a cardiac output
computer (American Edwards Laboratory, model COM-1 RS,
Irvin, CA, U.S.A.) was used. Left atrial pressure was monitored
via a left atrial pressure (LAP) line introduced into the left
atrial auricle. After the administraion of heparin sulfate (3
mg/kg), arterial and single venous cannulae were placed in
the ascending aorta and the right atrial auricle, respectively,
and cardiopulmonary bypass was started. The bypass circuit
consisted of two roller pumps (Sarns 7000, one-head, 6 inch,
Cheshire, CT/Shiley-Stockert double-head, 3 inch, Cheshire,
CT, U.S.A.), a bubble oxygenator (Bentley 10 plus, Irvin, CA,
U.S.A.), a heat exchanger, and 3/8 inch tubing (350 cm for
arterial and venous line, 100 cm for vent and sucker line).
The priming solution consisted of Ringer’s lactate (1,000 mL)
with heparin sulfate 1,100 I.U., sodium bicarbonate 20 mL,
mannitol 80 mL, and resultant hematocrit after the initiation
of bypass was 25-30%. The animals were treated during the
experiment and sacrificed at the end in accordance with the
‘Guide for the Care and Use of Laboratory Animals’ (National
Research Council, U.S.A.). 
Control group (Group I)
The total experimental time was 300 min: 120 min of CPB
and 180 min of post-bypass hemodynamic monitoring. Be-
fore the initiation of CPB, pulmonary artery pressure, left
atrial pressure, and cardiac output were measured for the cal-
culation of pre-bypass PVR. Perfusion flow rate was kept at
50 mL/kg/min with arterial blood pressure of 40-50 mmHg,
while crystalloid addition to a venous reservoir was limited
to less than 500 mL during bypass time in all cases. Rectal
temperature was lowered to 25℃ for 1 hr and was re-elevat-
ed to 37℃ before the termination of CPB, and normal sinus
rhythm was maintained during hypothermia in all cases. PO2
and PCO2 of perfusate were fixed to 100 mmHg and 40 mm
Hg, respectively, and acid-base status was regulated accord-
ing to the ‘alpha stat’ strategy. Heparin sulfate (1 mg/kg) was
administered to the bypass circuit 1 hr after the initiation of
cardiopulmonary bypass, and the ACT (activated coagulation
time) was kept greater than 480 sec in group I and greater
than 750 sec in group II by a celite activator during bypass
time. After the termination of CPB, protamine (4.5 mg/kg)
was administered, and ventilatory support was resumed. It
was attepted to maintain normal blood gas profile by fine
adjustments of ventilator settings throughout the post-bypass
period for 3 hr. Perfusate in the circuit and oxygenator was
recollected for post-bypass transfusion. The PVR prior to CPB
and during post-bypass period for 3 hr at 1 hr intervals were
calculated according to the following formula, which was
corrected by body weight. 
PVR=(mean PAP-mean LAP)/C.O.
Corrected PVR=PVR×body weight
The experimental animals were sacrificed three hours after
the termination of cardiopulmonary bypass, and right lung
tissue was obtained for both pathological examination and
water content measurement.
Aprotinin group (Group II)
Experimental conditions for group II were the same as gro-
up I, except for the use of aprotinin (Aprotimbin, BIOCHMIE
Ges.m.b.H,. Austria). The aprotinin administration regimen
was as follows:
Before bypass: 50,000 KIU/kg continuous infusion for 20 min
After bypass: 10,000 KIU/kg/hr for 3 hr
Mixed in priming solution: 50,000 KIU/kg
Statistical analysis
Post-bypass PVRs were compared with pre-bypass PVR
in all of the animals (n=10) using the Wilcoxon signed rank
test. For a comparison between the two groups, the ratio ofAprotinin Effect on Post-bypass Pulmonary Vascular Resistance 27
post-bypass PVR to pre-bypass PVR was calculated. The ra-
tios were compared between the two groups using the Wil-
coxon rank sum test. The water content of lung tissue was
also compared between the two groups non-parametrically.
p-value under 0.05 was considered significant. Analyses were
conducted using a PC-SAS 6.04 package.
RESULTS
Post-bypass changes of PVR
The ratios of post-bypass PVRs (at post-bypass 0, 1, 2 and
3 hr) to pre-bypass PVRs in all of the animals (n=10) were
1.44±0.42, 1.88±0.44, 1.95±0.34, 1.86±0.26, respec-
tively. The post-bypass PVRs were significantly higher than
pre-bypass PVRs in all of the dogs (n=10) throughout the
post-bypass period (p<0.01), but there was no difference in
the post-bypass PVR ratios (p>0.1). Post-bypass PVR in gro-
up I gradually increased after CPB while post-bypass PVRs
were similar in group II (Fig. 1). The ratio of the post-bypass
3 hr PVR to pre-bypass PVR was significantly greater in gro-
up I compared to group II (Table 1, p=0.0047). 
Water content of the lung
The water contents of the lung in group l and group II were
83±9.5% and 74±9.4%, respectively, but the difference
did not reach statistical significance (p=0.076) (Fig. 2).
Pathological findings
Pathological examination showed inflammatory cell infil-
tration in the pulmonary interstitium, destruction of the alve-
olar structure, and vasoconstriction of small to medium sized
pulmonary arteries in group I. Near normal histology was
observed in group II (Fig. 3). 
DISCUSSION
The surgical correction of many congenital and acquired
cardiac diseases has been made possible by theoretical and
technical developments in cardiopulmonary bypass (CPB)
ever since this innovative technique was introduced in the
early 1950s. Whole body inflammatory response due to con-
tact activation of blood components exposed to foreign mate-
rials in bypass circuit, however, is still an unsolved problem,
which causes a variety of post-bypass complications in many
organs (16, 17). The lung is deemed the most important or-
gan in this regard because it is susceptible to CPB-induced
injury due to its weak supporting tissue and abundant vas-
cularity and because abnormal gas exchange and instability
of PVR have a devastating impact on postoperative course
after cardiac surgery. Elevation of PVR after extra-corporeal
circulation is thought to originate from endothelial dysfunc-
tion. Postoperative pulmonary vascular instability has special
implications in pediatric patients because it is associated with
pulmonary hypertensive crisis in patients with preoperative
pulmonary hypertension, hemodynamic instability after pal-
liative operations in which postoperative systemic circulation
is determined by the balance between PVR and SVR (syste-
mic vascular resistance), and inadequate oxygenation after one
ventricle repair (bi-directional cavo-pulmonary shunt or Fon-
tan operation). Several clinical studies regarding the benefi-
PVR, pre-bypass PVR; PVR 0-3, post-bypass 0-3 hr PVR; NS, not signifi-
cant.
Control Aprotinin  p-value
PVR0/PVR 1.28 1.58 NS
PVR1/PVR 1.82 1.73 NS
PVR2/PVR 1.9 1.66 NS
PVR3/PVR 2.14 1.5 0.0047
Table 1. Comparison of post-bypass PVR/pre-bypass PVR be-
tween the control and the aprotinin groups
Fig. 1. The ratio of post-bypass over pre-bypass PVR in the con-
trol and the aprotinin groups. 
PVR, prebypass PVR; PVR 0-3, postbypass 0-3 hr PVR.
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Fig. 2. Water content (%) of the lung in the control and the apro-
tinin groups.
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cial effect of aprotinin on postoperative course after one ven-
tricle repair have been reported (2), and these observations
imply that aprotinin can be used for both hemostatic (17-22)
and anti-inflammatory purposes. The mechanisms of anti-
inflammatory effects of aprotinin is not fully understood, but
various indirect evidences have been accumulated through
in vivo and in vitro studies including the attenuation of post-
bypass elevation of interleukin-8 in BALF (bronchial alveo-
lar lavage fluid) (23), suppression of complement activation
upon hemodialysis (24), reduction of inflammatory media-
tors in an experimental bypass circuit (25), the beneficial effect
of aprotinin on post-bypass cardiac function in a swine experi-
mental model (26), beneficial effect of aprotinin on renal func-
tion recovery after cardiopulmonary bypass (27), reduction
of post-bypass intra-bronchial i-NOS (inducible NO synthase)
during cardiopulmonary bypass (28), reduction of the con-
centration of cell adhesion molecules (ICAM, VCAM, ELAM)
(29), the beneficial effect of aprotinin on neurologic recovery
after circulatory arrest (30), and so forth. With respect to its
effect on the pulmonary vascular bed, several hypothetical
mechanisms have been postulated including inactivation of
the kallikrein-bradykinin system, suppression of complement
activation, suppression of the secretion of vaso-active sub-
stances (thromboxane A2, endothelin) (31), protection of pul-
monary vascular endothelial functions, and maintenance of
the production of nitric oxide. 
One of the limitations of this study is that the dose of apro-
tinin is arbitrary and relatively ‘high’ compared to other expe-
riments. The aprotinin regimen of this experiment is based
on a clinical report of ‘high dose’ aprotinin treatment for pedi-
atric cardiac patients (32). Aprotinin doses used in other ex-
periments, however, vary widely from one another (33), and
there is no recommended dose of aprotinin with which the
anti-inflammaotry effect is anticipated. Furthermore, hemodi-
lution in small children (34, 35) during cardiopulmonary by-
pass can make it more difficult to predict adequate serum
aprotinin levels in a clinical setting (20, 25). Therefore, direct
measurement of serum aprotinin levels may be helpful for
the precise evaluation of the effect of aprotinin. 
Aprotinin has already been widely used as a hemostatic
agent in various types of open heart surgery, and the indica-
tion of aprotinin use can be extended if its ability to attenu-
ate post-bypass lung injury is verified, especially in the pedi-
atric patient population. Additional experimental and clini-
cal studies are needed to find out the exact mechanisms of
the effects of aprotinin on the pulmonary vascular bed, and
also to determine the ideal regimen of aprotinin in various
clinical settings. 
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